Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Single Doses of NV-5138 in Healthy Volunteers and Subjects With Treatment-Resistant Depression

NCT03606395 is registered in ClinicalTrials.gov with Navitor Pharmaceuticals, Inc. as lead sponsor.

NCT NCT03606395
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03606395 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Single Doses of NV-5138 in Healthy Volunteers and Subjects With Treatment-Resistant Depression
Lead sponsor
Navitor Pharmaceuticals, Inc.
Phase
Phase 1
Overall status
Completed
Start date
June 6, 2018
Completion date
July 7, 2019
Enrollment
80 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

treatment resistant depression